These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 16415488)

  • 1. The future of traditional nonsteroidal antiinflammatory drugs and cyclooxygenase-2 inhibitors in the treatment of inflammation and pain.
    Sciulli MG; Capone ML; Tacconelli S; Patrignani P
    Pharmacol Rep; 2005; 57 Suppl():66-85. PubMed ID: 16415488
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-inflammatory drugs in the 21st century.
    Rainsford KD
    Subcell Biochem; 2007; 42():3-27. PubMed ID: 17612044
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting inhibition of COX-2: a review of patents, 2002-2006.
    da Cunha EF; Ramalho TC; Josa D; Caetano MS; de Souza TC
    Recent Pat Inflamm Allergy Drug Discov; 2007 Jun; 1(2):108-23. PubMed ID: 19075973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Variability in the response to non-steroidal anti-inflammatory drugs: mechanisms and perspectives.
    Bruno A; Tacconelli S; Patrignani P
    Basic Clin Pharmacol Toxicol; 2014 Jan; 114(1):56-63. PubMed ID: 23953622
    [TBL] [Abstract][Full Text] [Related]  

  • 5. COXIBs, CINODs and H₂S-releasing NSAIDs: current perspectives in the development of safer non steroidal anti-inflammatory drugs.
    Fiorucci S; Distrutti E
    Curr Med Chem; 2011; 18(23):3494-505. PubMed ID: 21756233
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical use and pharmacological properties of selective COX-2 inhibitors.
    Shi S; Klotz U
    Eur J Clin Pharmacol; 2008 Mar; 64(3):233-52. PubMed ID: 17999057
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The cardiovascular pharmacology of COX-2 inhibition.
    Fries S; Grosser T
    Hematology Am Soc Hematol Educ Program; 2005; ():445-51. PubMed ID: 16304418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical pharmacology of selective COX-2 inhibitors.
    Capone ML; Tacconelli S; Sciulli MG; Patrignani P
    Int J Immunopathol Pharmacol; 2003; 16(2 Suppl):49-58. PubMed ID: 14552704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclooxygenase inhibitors: From pharmacology to clinical read-outs.
    Patrignani P; Patrono C
    Biochim Biophys Acta; 2015 Apr; 1851(4):422-32. PubMed ID: 25263946
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical pharmacology of lumiracoxib, a second-generation cyclooxygenase 2 selective inhibitor.
    Bannwarth B; Berenbaum F
    Expert Opin Investig Drugs; 2005 Apr; 14(4):521-33. PubMed ID: 15882125
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation.
    Chen YF; Jobanputra P; Barton P; Bryan S; Fry-Smith A; Harris G; Taylor RS
    Health Technol Assess; 2008 Apr; 12(11):1-278, iii. PubMed ID: 18405470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Update on cyclooxygenase inhibitors: has a third COX isoform entered the fray?
    Hersh EV; Lally ET; Moore PA
    Curr Med Res Opin; 2005 Aug; 21(8):1217-26. PubMed ID: 16083531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Selective inhibitors of cyclooxygenase-2 (COX-2), celecoxib and parecoxib: a systematic review].
    Mateos JL
    Drugs Today (Barc); 2010 Feb; 46 Suppl A():1-25. PubMed ID: 20224826
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An evidence-based evaluation of the gastrointestinal safety of coxibs.
    Bombardier C
    Am J Cardiol; 2002 Mar; 89(6A):3D-9D. PubMed ID: 11909555
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclooxygenase-2 inhibitors: a painful lesson.
    Sanghi S; MacLaughlin EJ; Jewell CW; Chaffer S; Naus PJ; Watson LE; Dostal DE
    Cardiovasc Hematol Disord Drug Targets; 2006 Jun; 6(2):85-100. PubMed ID: 16787194
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacodynamic of cyclooxygenase inhibitors in humans.
    Capone ML; Tacconelli S; Di Francesco L; Sacchetti A; Sciulli MG; Patrignani P
    Prostaglandins Other Lipid Mediat; 2007 Jan; 82(1-4):85-94. PubMed ID: 17164136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonsteroidal anti-inflammatory drugs and cardiovascular safety - translating pharmacological data into clinical readouts.
    Tacconelli S; Bruno A; Grande R; Ballerini P; Patrignani P
    Expert Opin Drug Saf; 2017 Jul; 16(7):791-807. PubMed ID: 28569569
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostanoids and inflammatory pain.
    Chen L; Yang G; Grosser T
    Prostaglandins Other Lipid Mediat; 2013; 104-105():58-66. PubMed ID: 22981510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Druggable Prostanoid Pathway.
    Mazaleuskaya LL; Ricciotti E
    Adv Exp Med Biol; 2020; 1274():29-54. PubMed ID: 32894506
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular effects of cyclooxygenase-2 inhibitors: a mechanistic and clinical perspective.
    Patrono C
    Br J Clin Pharmacol; 2016 Oct; 82(4):957-64. PubMed ID: 27317138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.